about
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Symptoms after mould exposure including Stachybotrys chartarum, and comparison with darkroom disease.Diisocyanate and non-diisocyanate sensitizer-induced occupational asthma frequency during 2003 to 2007 in Ontario, Canada.Reduction in diisocyanate and non-diisocyanate sensitizer-induced occupational asthma in Ontario.Validation of the Brazilian-Portuguese version of the European Community Respiratory Health Survey in asthma patients.Prevalence and risk of asthma symptoms among firefighters in São Paulo, Brazil: a population-based study.Work-related asthma in health care in Ontario.Methacholine vs adenosine on intra and extrathoracic airway hyperresponsiveness in patients with cough variant asthma.Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma.Relationship between peak expiratory flow rate and shoulders posture in healthy individuals and moderate to severe asthmatic patients.The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.Air trapping: The major factor limiting diaphragm mobility in chronic obstructive pulmonary disease patientsHigh-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled studySearch for chronic beryllium disease among sarcoidosis patients in Ontario, CanadaCutaneous and respiratory symptoms among professional cleanersCR3 (CD11b/CD18) activation of nasal neutrophils: a measure of upper airway endotoxin exposureFactors influencing respirator use at work in respiratory patientsOutcome of work-related asthma exacerbations in Quebec and Ontario
P50
Q35822146-3D7934D5-2782-425C-9279-C8ABFF522B5BQ37606539-F732E8D7-502C-460A-A785-0B92F3632CEEQ38242886-08319B22-64D2-479A-83F6-E0570B269886Q38439866-EE8B045C-6587-4E09-856B-F21C81C36F61Q43632024-3A283ED8-96F5-493D-A158-E4CA70DD94D1Q45897550-C71C1571-AA8E-4431-887B-F0B96CD27AD8Q45913010-1C7FB7A2-BB58-419D-B15A-FF252B771A8EQ46660333-ADBDE300-C467-4E2F-8867-E581AEB3E4D5Q46817031-D32A914C-719C-4B7A-B278-766A0FBE40DCQ47682678-8D462B1D-3C30-48F6-A8BD-3DC93AB20A32Q51128845-F5A4162E-9E2E-4FFD-9935-AA597CE424D5Q80498697-14CB60EA-F1E9-4187-809C-EA7D403D1B69Q80668568-DB557BBF-6144-493B-AFE8-A8DC1489D121Q83602986-A173D745-1A7C-4D0F-A8EC-8FAD906527DDQ83810269-EA6F9792-A0FB-408E-81BF-95E01A123F89Q84797751-0F0D32CE-D134-4727-8950-1515DB93AB36Q85036836-C1B6373E-5C6D-4AFB-856A-DE465F8D151FQ85893234-3E4D9308-A26F-4734-B0FC-6194DC61BFE4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marcos Ribeiro
@ast
Marcos Ribeiro
@en
Marcos Ribeiro
@es
Marcos Ribeiro
@nl
Marcos Ribeiro
@sl
type
label
Marcos Ribeiro
@ast
Marcos Ribeiro
@en
Marcos Ribeiro
@es
Marcos Ribeiro
@nl
Marcos Ribeiro
@sl
prefLabel
Marcos Ribeiro
@ast
Marcos Ribeiro
@en
Marcos Ribeiro
@es
Marcos Ribeiro
@nl
Marcos Ribeiro
@sl
P106
P21
P31
P496
0000-0002-4169-5262